phrykt

Madrigal Pharmaceuticals, Inc. (MDGL): who owns it and who trades it

As of Nov 16, 2026, MDGL insiders reported 177 open-market sales worth $69.4M and 5 purchases worth $35M in the last 12 months, with 89% of the sale value made under pre-set 10b5-1 plans. The largest seller was Paul A Friedman (Director), with $26.7M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Madrigal Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MDGL

413 funds and institutions reported MDGL shares worth $12.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 9.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Baker Bros. Advisors LP9.3%
Rtw Investments, LP8.6%
Jupiter Topco LLC8.4%
Avoro Capital Advisors LLC8.0%
Paulson & Co. Inc.5.8%
BlackRock, Inc.5.2%
Vanguard Capital Management LLC3.6%
Wellington Management Group LLP3.6%
Vanguard Portfolio Management LLC3.4%
State Street Corp2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP2.14M9.30%$1.2B+0%
Rtw Investments, LP1.99M8.65%$1.1BNo change
Jupiter Topco LLC1.94M8.40%$1B–
Avoro Capital Advisors LLC1.83M7.95%$984M+1%
Paulson & Co. Inc.1.34M5.81%$720M-4%
BlackRock, Inc.1.20M5.21%$645M-23%
Vanguard Capital Management LLC835,6683.62%$449M+1%
Wellington Management Group LLP825,7143.58%$443M+19%
Vanguard Portfolio Management LLC781,7313.39%$420M-7%
State Street Corp527,0572.29%$283M-14%
Citadel Advisors LLC507,2332.20%$272M+12%
UBS Group AG401,7081.74%$216M+241%
Geode Capital Management, LLC374,8801.63%$201M-18%
FMR LLC (Fidelity)356,2011.54%$191M-30%
William Blair Investment Management, LLC324,1231.41%$174M-5%
Invesco Ltd.301,4351.31%$162M-9%
Armistice Capital, LLC288,0001.25%$155M+9%
Lord, Abbett & Co. LLC281,5001.22%$151M+16%
Assenagon Asset Management S.A.248,4281.08%$133M+1449%
Goldman Sachs Group Inc246,2801.07%$132M-11%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MDGL insiders reported $35M of open-market purchases and $69.4M of sales. 89% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$35M
5 trades, 1 people
Sales, 12 months
$69.4M
177 trades, 8 people
Sales under a 10b5-1 plan
89%
Share of sale value
Latest trade
Nov 6, 2026
Filed Nov 6, 2026

Purchases and sales by month

$35M$35MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 6, 2026Baker Bros. Advisors Lp +5DirectorPurchase60,400$383.01$23.1MForm 4
Nov 6, 2026Baker Bros. Advisors Lp +5DirectorPurchase13,740$388.29$5.3MForm 4
Nov 6, 2026Baker Bros. Advisors Lp +5DirectorPurchase2,000$396.61$793KForm 4
Nov 6, 2026Shannon T KelleyGeneral CounselSale plan1,077$400.00$431KForm 4
Nov 4, 2026Baker Bros. Advisors Lp +5DirectorPurchase5,586$366.99$2.1MForm 4
Nov 4, 2026Baker Bros. Advisors Lp +5DirectorPurchase10,080$368.11$3.7MForm 4
Sep 11, 2026William John SiboldCEOSale plan60$533.09$32KForm 4
Sep 11, 2026William John SiboldCEOSale plan218$535.94$117KForm 4
Sep 11, 2026William John SiboldCEOSale plan160$537.62$86KForm 4
Sep 11, 2026William John SiboldCEOSale plan687$540.59$371KForm 4
Sep 11, 2026William John SiboldCEOSale plan368$541.64$199KForm 4
Sep 11, 2026William John SiboldCEOSale plan1,202$542.60$652KForm 4
Sep 11, 2026William John SiboldCEOSale plan1,539$544.02$837KForm 4
Sep 11, 2026William John SiboldCEOSale plan761$544.83$415KForm 4
Sep 11, 2026William John SiboldCEOSale plan120$546.38$65.6KForm 4
Sep 11, 2026William John SiboldCEOSale plan106$534.06$56.6KForm 4
Sep 9, 2026William John SiboldCEOSale plan160$542.55$86.8KForm 4
Sep 9, 2026William John SiboldCEOSale plan131$527.88$69.2KForm 4
Sep 9, 2026William John SiboldCEOSale plan347$529.27$184KForm 4
Sep 9, 2026William John SiboldCEOSale plan522$530.23$277KForm 4
Sep 9, 2026William John SiboldCEOSale plan368$531.99$196KForm 4
Sep 9, 2026William John SiboldCEOSale plan512$533.09$273KForm 4
Sep 9, 2026William John SiboldCEOSale plan396$534.20$212KForm 4
Sep 9, 2026William John SiboldCEOSale plan644$535.27$345KForm 4
Sep 9, 2026William John SiboldCEOSale plan1,040$536.11$558KForm 4
Sep 9, 2026William John SiboldCEOSale plan640$537.17$344KForm 4
Sep 9, 2026William John SiboldCEOSale plan520$538.30$280KForm 4
Sep 9, 2026William John SiboldCEOSale plan215$539.03$116KForm 4
Sep 9, 2026William John SiboldCEOSale plan505$540.19$273KForm 4
Sep 9, 2026William John SiboldCEOSale plan362$541.65$196KForm 4
Aug 17, 2026Shannon T KelleyGeneral CounselSale664$514.97$342KForm 4
Jul 20, 2026William John SiboldCEOSale545$544.71$297KForm 4
Jul 20, 2026William John SiboldCEOSale280$555.05$155KForm 4
Jul 20, 2026William John SiboldCEOSale1$550.72$551Form 4
Jul 20, 2026William John SiboldCEOSale153$550.01$84.2KForm 4
Jul 20, 2026William John SiboldCEOSale47$548.87$25.8KForm 4
Jul 20, 2026William John SiboldCEOSale680$547.70$372KForm 4
Jul 20, 2026William John SiboldCEOSale269$547.08$147KForm 4
Jul 20, 2026William John SiboldCEOSale275$545.71$150KForm 4
Jul 20, 2026William John SiboldCEOSale110$543.79$59.8KForm 4
Jul 20, 2026William John SiboldCEOSale140$542.75$76KForm 4
Jun 1, 2026David SoergelChief Medical OfficerSale plan1,042$495.74$517KForm 4
May 22, 2026Richard S LevyDirectorSale plan80$519.98$41.6KForm 4
May 22, 2026Richard S LevyDirectorSale plan782$518.76$406KForm 4
May 22, 2026Richard S LevyDirectorSale plan1,497$517.59$775KForm 4
May 22, 2026Richard S LevyDirectorSale plan723$516.87$374KForm 4
May 22, 2026Richard S LevyDirectorSale plan657$515.92$339KForm 4
May 22, 2026Richard S LevyDirectorSale plan343$514.67$177KForm 4
May 22, 2026Richard S LevyDirectorSale plan40$512.97$20.5KForm 4
May 22, 2026Richard S LevyDirectorSale plan439$512.50$225KForm 4
May 22, 2026Richard S LevyDirectorSale plan610$511.40$312KForm 4
May 22, 2026Richard S LevyDirectorSale plan151$510.36$77.1KForm 4
May 22, 2026Richard S LevyDirectorSale plan40$506.68$20.3KForm 4
May 22, 2026Richard S LevyDirectorSale plan320$508.24$163KForm 4
May 18, 2026David SoergelChief Medical OfficerSale844$515.90$435KForm 4
Mar 6, 2026Mardi DierCFOSale plan160$434.20$69.5KForm 4
Mar 6, 2026Mardi DierCFOSale plan80$435.32$34.8KForm 4
Mar 6, 2026Mardi DierCFOSale plan80$436.69$34.9KForm 4
Mar 6, 2026Mardi DierCFOSale plan40$437.65$17.5KForm 4
Mar 6, 2026Mardi DierCFOSale plan646$431.94$279KForm 4
Mar 6, 2026Mardi DierCFOSale plan40$425.08$17KForm 4
Mar 6, 2026Mardi DierCFOSale plan420$426.86$179KForm 4
Mar 6, 2026Mardi DierCFOSale plan80$427.85$34.2KForm 4
Mar 6, 2026Mardi DierCFOSale plan160$429.00$68.6KForm 4
Mar 6, 2026Mardi DierCFOSale plan40$429.58$17.2KForm 4
Mar 6, 2026Mardi DierCFOSale plan120$430.90$51.7KForm 4
Mar 6, 2026Mardi DierCFOSale plan116$432.56$50.2KForm 4
Mar 6, 2026William John SiboldCEOSale1,663$431.94$718KForm 4
Mar 6, 2026Shannon T KelleyGeneral CounselSale360$431.94$155KForm 4
Mar 6, 2026Carole HuntsmanChief Commercial OfficerSale419$431.94$181KForm 4
Mar 6, 2026Rebecca TaubDirectorSale491$431.94$212KForm 4
Mar 2, 2026Mardi DierCFOSale1,183$427.21$505KForm 4
Jan 26, 2026Carole HuntsmanChief Commercial OfficerSale plan570$494.59$282KForm 4
Jan 26, 2026Carole HuntsmanChief Commercial OfficerSale plan340$492.42$167KForm 4
Jan 26, 2026William John SiboldCEOSale1,577$492.42$777KForm 4
Jan 26, 2026Rebecca TaubDirectorSale647$492.42$319KForm 4
Jan 20, 2026Shannon T KelleyGeneral CounselSale plan429$501.40$215KForm 4
Jan 20, 2026Shannon T KelleyGeneral CounselSale plan263$490.77$129KForm 4
Jan 20, 2026Rebecca TaubDirectorSale2,238$490.77$1.1MForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan280$551.24$154KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan2,450$517.86$1.3MForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan681$521.03$355KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan840$521.98$438KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan970$523.00$507KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan1,199$524.10$628KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan2,432$525.05$1.3MForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan1,066$526.00$561KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan1,560$526.97$822KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan575$528.18$304KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan691$529.17$366KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan166$529.76$87.9KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan280$530.69$149KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan80$532.50$42.6KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan332$534.16$177KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan148$535.29$79.2KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan473$536.02$254KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan487$536.88$261KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan80$537.85$43KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan480$539.23$259KForm 4
Jan 9, 2026Paul A FriedmanDirectorSale plan600$540.36$324KForm 4

Latest 100 of 182 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Baker Bros. Advisors LpDirector$35M–Nov 6, 2026
Paul A FriedmanDirector–$26.7MJan 9, 2026
Rebecca TaubDirector–$21.7MMar 6, 2026
William John SiboldPresident and CEO, Director–$10.5MSep 11, 2026
Mardi DierEVP and CFO–$3.8MMar 6, 2026
Richard S LevyDirector–$2.9MMay 22, 2026
Carole HuntsmanChief Commercial Officer–$1.7MMar 6, 2026
Shannon T KelleyGeneral Counsel–$1.3MNov 6, 2026
David SoergelChief Medical Officer–$952KJun 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MDGL short interest

Moderate short interest. 9.2% of MDGL shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 45%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.14M MDGL shares were sold short, 9.2% of the shares outstanding, down 2.6% from the report before. At the average daily volume of 279,558 shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

9.20%May 15Oct 3018.2%

Days to cover

7.6May 15Oct 3015.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.14M9.20%-3%279,5587.6
Oct 15, 20262.19M9.50%-8%303,1137.2
Sep 30, 20262.40M10.37%+6%245,0019.8
Sep 15, 20262.25M9.76%+1%197,43911.4
Aug 31, 20262.24M9.70%+11%236,7439.5
Aug 14, 20262.03M8.77%+3%335,0126.0
Jul 31, 20261.97M8.51%-5%406,2504.8
Jul 15, 20262.06M8.95%-42%297,2796.9
Jun 30, 20263.53M15.30%-7%568,8136.2
Jun 15, 20263.78M16.40%-1%263,95814.3
May 29, 20263.82M16.58%-2%271,57414.1
May 15, 20263.90M16.90%+1%316,16412.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Madrigal Pharmaceuticals company events

Madrigal Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026LeadershipThe Board of Directors of Madrigal Pharmaceuticals, Inc. expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August… Filing
  3. Jul 30, 2026ResultsReleased financial results. Filing
  4. Jun 17, 2026LeadershipAt the annual meeting of stockholders of Madrigal Pharmaceuticals, Inc., the Company's stockholders approved the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan, which was previously adopted by the Company's Board of Directors. Filing
  5. May 6, 2026ResultsReleased financial results. Filing
  6. Apr 28, 2026LeadershipThe Board of Directors of Madrigal Pharmaceuticals, Inc. completed a process to reclassify the membership of the Board’s three classes of directors to achieve a more equal apportionment of membership among the three classes following its Annual Meeting of Stockholders to be held on June 17, 2026. Filing
  7. Feb 19, 2026ResultsReleased financial results. Filing
  8. Jan 30, 2026AgreementMadrigal Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche. Filing
  9. Dec 11, 2025LeadershipThe Board of Directors of Madrigal Pharmaceuticals, Inc. appointed Rita Thakkar as Senior Vice President and Chief Accounting Officer of the Company, effective January 12, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Madrigal Pharmaceuticals financials

Famous investors that hold MDGL

4 of the 50 well-known investors we track reported holding MDGL in their latest 13F filing. The largest position is Ken Griffin's, worth $37.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202674,915$37.8M0.0%-85%
Ray Dalio · Bridgewater AssociatesQ3 202653,627$27M0.1%New
Jim Simons · Renaissance TechnologiesQ3 202644,222$22.3M0.0%-4%
Israel Englander · Millennium ManagementQ3 20268,295$4.2M0.0%-90%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MDGL in the last 120 days.

FiledHolderFormStake
Nov 16, 2026RTW Investments, LP13G/A1.4%
Nov 16, 2026RTW Investments, LP13G/A1.4%
Nov 6, 2026Baker Bros. Advisors LP13D/A10.0%
Nov 6, 2026Baker Bros. Advisors LP13D/A10.0%

Questions about Madrigal Pharmaceuticals, Inc. (MDGL) stock

Who owns the most MDGL stock?

The largest reported owner of Madrigal Pharmaceuticals, Inc. (MDGL) is Baker Bros. Advisors LP, with 9.3% of the company. In total, 413 funds and institutions reported holding MDGL at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are MDGL insiders buying or selling?

In the last 12 months, MDGL insiders reported 5 open-market purchases worth $35M and 177 sales worth $69.4M. The latest trade was on Nov 6, 2026. See every trade.

What is the short interest in MDGL?

As of Oct 30, 2026, 2.14M MDGL shares were sold short, 9.2% of the shares outstanding, down 2.6% from the report before. At the average daily volume of 279,558 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Which famous investors hold MDGL?

4 of the 50 well-known investors we track reported MDGL in their latest 13F filing, including Ken Griffin, Ray Dalio, Jim Simons. The largest position is worth $37.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.